Sign In
Buy NEO
$10.14
+0.0200 (+0.198%)
At Close: Jun 03, 2026
NeoGenomics to Participate in Upcoming June Investor Conferences
07:05am, Tuesday, 20'th May 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the William Blair Growth Stock Conference in Chicago and the Jefferies Global Healthcare Conference in New York.
It's Not Too Late to Jump on These Under-the-Radar Momentum Plays
09:32am, Tuesday, 06'th May 2025
Those subscribing to a momentum investing strategy tend to believe that stocks experiencing price increases tend to rally, so long as both internal and external conditions don't change. Of course, no
NEO Battery Materials Appoints Dr. Matthew Dawson, CEO of Elementium Materials, as Senior Scientific Advisor
08:38am, Friday, 02'nd May 2025
TORONTO, May 02, 2025 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “Company”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-run
NeoGenomics Pays Off 1.25% Convertible Senior Notes
07:05am, Thursday, 01'st May 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics has paid off in full the remaining $201.25 million in principal amount outstanding of its 1.25% Convertible Senior Notes.
NeoGenomics Q1 Earnings: The Stock Price Drop Is A Gift (Rating Upgrade)
09:00am, Wednesday, 30'th Apr 2025
NeoGenomics' recent 32.23% stock price decline post-Q1 earnings miss is seen as a buying opportunity due to overreaction and long-term growth potential. Despite a slight revenue miss, the company's lo
NeoGenomics, Inc (NEO) Q1 2025 Earnings Call Transcript
12:18pm, Tuesday, 29'th Apr 2025
NeoGenomics, Inc (NASDAQ:NEO ) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Company Participants Kendra Sweeney - Vice President, Investor Relations and ESG Tony Zook - Chief Executive O
NeoGenomics (NEO) Reports Break-Even Earnings for Q1
09:40am, Tuesday, 29'th Apr 2025
NeoGenomics (NEO) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of a loss of $0.02. This compares to loss of $0.02 per share a year ago.
NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform
08:00am, Tuesday, 29'th Apr 2025
FORT MYERS, Fla. and FREMONT, Calif.
NeoGenomics Reports First Quarter 2025 Results
07:30am, Tuesday, 29'th Apr 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its first-quarter results for the period ended March 31, 2025.
TORONTO, April 25, 2025 (GLOBE NEWSWIRE) -- NEO Battery Materials Ltd. (“NEO” or the “Company”) (T S X V : NBM) (OTC: NBMFF), a low-cost silicon anode materials developer that enables longer-r
NeoGenomics (NEO) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
11:06am, Tuesday, 22'nd Apr 2025
NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NeoGenomics to Showcase PanTracer LBx Validation Study at AACR Annual Meeting
07:05am, Tuesday, 22'nd Apr 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced analytical validation of its PanTracer LBx™ assay, to be presented with five other abstracts at the AACR Annual Meeting 2025.
-- Trial Read-Out Data Expected in Early 2026 -- CALABASAS, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focu
NeOnc Technologies Announces Near Completion of Phase I Enrollment for NEO212 Brain Cancer Therapy
04:05pm, Tuesday, 08'th Apr 2025
CALABASAS, Calif., April 08, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage biopharmaceutical company focused on innovative treatments for central nervous
NeoGenomics to Report First Quarter 2025 Financial Results on April 29, 2025
07:05am, Tuesday, 08'th Apr 2025
FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its first quarter 2025 financial results prior to the open of the U.S. financial markets on Tuesday, April 29, 2025.
